Vimpat and Entresto drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Vimpat (lacosamide) and Entresto (sacubitril; valsartan). Common drug interactions include mobility decreased among females and circulatory collapse among males.

The phase IV clinical study analyzes what interactions people have when they take Vimpat and Entresto. It is created by eHealthMe based on reports of 21 people who take the same drugs from the FDA, and is updated regularly.

What is Vimpat?

Vimpat has active ingredients of lacosamide. It is often used in epilepsy. eHealthMe is studying from 20,831 Vimpat users. Check the latest studies of Vimpat.

What is Entresto?

Entresto has active ingredients of sacubitril; valsartan. eHealthMe is studying from 126,628 Entresto users. Check the latest studies of Entresto.

On Jul, 15, 2026

21 people who take Vimpat and Entresto together, and have interactions are studied.

What are the common drug interactions of Vimpat and Entresto, by gender? *:

female:

Mobility decreased (ability to move is reduced)
Myocardial infarction (destruction of heart tissue resulting from obstruction of the blood supply to the heart muscle)
Aortic valve incompetence
Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
Bradycardia (abnormally slow heart action)
Cardiac failure
Confusional state
Delirium (wild excitement)
Diarrhoea
Hepatic enzyme increased

male:

Circulatory collapse
Dilated cardiomyopathy
Partial seizures with secondary generalisation (partial seizure may spread within the brain, a process known as secondary generalization)
Tremor (trembling or shaking movements in one or more parts of your body)
Drug-induced liver injury (diseases of the liver that are caused by physician-prescribed medications)
Septic shock (shock due to blood infection)
Death
Interstitial lung disease
Hypoaesthesia (reduced sense of touch or sensation)
Hyponatraemia (abnormally low level of sodium in the blood; associated with dehydration)

What are the common drug interactions of Vimpat and Entresto, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

Death
Partial seizures with secondary generalisation (partial seizure may spread within the brain, a process known as secondary generalization)

40-49:

n/a

50-59:

Drug-induced liver injury (diseases of the liver that are caused by physician-prescribed medications)
Death

60+:

Circulatory collapse
Dilated cardiomyopathy
Eosinophilia (eosinophil count in the peripheral blood exceeds)
Hypoaesthesia (reduced sense of touch or sensation)
Lung infiltration (a substance that normally includes fluid, inflammatory exudates or cells that fill a region of lung)
Malignant neoplasm progression (cancer tumour came back)
Pruritus (severe itching of the skin)
Rash papular (redness with papule)
Tremor (trembling or shaking movements in one or more parts of your body)
Mobility decreased (ability to move is reduced)

What are the existing conditions these people have? *

Cardiac Failure: 4 people, 19.05%
Type 2 Diabetes: 3 people, 14.29%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 3 people, 14.29%
Infection: 3 people, 14.29%
High Blood Cholesterol: 3 people, 14.29%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 3 people, 14.29%
Enlarged Prostate: 3 people, 14.29%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 3 people, 14.29%

* Approximation only. Some reports may have incomplete information.

Do you take Vimpat and Entresto?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously